- Home
- TDTH vs VYNE Comparison
TDTH vs VYNE Comparison
Compare TDTH & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDTH
- VYNE
- Stock Information
- Founded
- TDTH 2014
- VYNE 2003
- Country
- TDTH Singapore
- VYNE United States
- Employees
- TDTH N/A
- VYNE N/A
- Industry
- TDTH
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- TDTH
- VYNE Health Care
- Exchange
- TDTH NYSE
- VYNE Nasdaq
- Market Cap
- TDTH 42.7M
- VYNE 35.7M
- IPO Year
- TDTH 2024
- VYNE 2018
- Fundamental
- Price
- TDTH $0.22
- VYNE $1.30
- Analyst Decision
- TDTH
- VYNE Strong Buy
- Analyst Count
- TDTH 0
- VYNE 2
- Target Price
- TDTH N/A
- VYNE $6.25
- AVG Volume (30 Days)
- TDTH 1.2M
- VYNE 220.5K
- Earning Date
- TDTH 05-25-2025
- VYNE 05-08-2025
- Dividend Yield
- TDTH N/A
- VYNE N/A
- EPS Growth
- TDTH N/A
- VYNE N/A
- EPS
- TDTH N/A
- VYNE N/A
- Revenue
- TDTH $465,435.00
- VYNE $605,000.00
- Revenue This Year
- TDTH N/A
- VYNE N/A
- Revenue Next Year
- TDTH N/A
- VYNE N/A
- P/E Ratio
- TDTH N/A
- VYNE N/A
- Revenue Growth
- TDTH N/A
- VYNE 43.03
- 52 Week Low
- TDTH $0.20
- VYNE $1.27
- 52 Week High
- TDTH $4.74
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- TDTH N/A
- VYNE 34.90
- Support Level
- TDTH N/A
- VYNE $1.27
- Resistance Level
- TDTH N/A
- VYNE $1.41
- Average True Range (ATR)
- TDTH 0.00
- VYNE 0.12
- MACD
- TDTH 0.00
- VYNE -0.01
- Stochastic Oscillator
- TDTH 0.00
- VYNE 5.46
About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B
Trident Digital Tech Holdings is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.